|Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych||Co-Founder, Exec. Chairman, CEO & MD||351.19k||N/A||1955|
|Ms. Kathryn Andrews B.Com, CPA||Chief Financial Officer||119.32k||N/A||1967|
|Ms. Dianne M. Angus||Chief Operating Officer||274.52k||N/A||1960|
|Dr. David A. Stamler M.D.||Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board||45.93k||N/A||1961|
|Prof. Rudolph Emile Tanzi Ph.D.||Chief Scientific Advisor and Member of R&D Advisory Board||N/A||N/A||N/A|
Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.
Prana Biotechnology Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.